Moody Lynn & Lieberson LLC grew its position in Celgene Co. (NASDAQ:CELG) by 78.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 113,836 shares of the biopharmaceutical company’s stock after buying an additional 49,978 shares during the quarter. Celgene makes up about 2.0% of Moody Lynn & Lieberson LLC’s portfolio, making the stock its 14th largest holding. Moody Lynn & Lieberson LLC’s holdings in Celgene were worth $16,600,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI lifted its position in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. lifted its position in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares in the last quarter. Guidant Wealth Advisors purchased a new position in Celgene during the third quarter worth approximately $119,000. Motco lifted its position in Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares in the last quarter. Finally, Balentine LLC lifted its position in Celgene by 83.5% during the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 481 shares in the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.
Shares of Celgene Co. (NASDAQ:CELG) opened at $104.58 on Friday. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $82,340.00, a price-to-earnings ratio of 24.67, a PEG ratio of 0.68 and a beta of 1.77.
CELG has been the topic of a number of analyst reports. BMO Capital Markets lifted their price objective on Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer reiterated a “buy” rating and set a $170.00 price objective on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a research report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley upgraded Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $131.18.
WARNING: This piece was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/12/moody-lynn-lieberson-llc-grows-stake-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.